Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand, Denmark
Edarbi 20 mg tablets.
Edarbi 40 mg tablets.
Edarbi 80 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Edarbi 20 mg tablets: White to nearly white round tablets, 6.0 mm in diameter, debossed “ASL” on one side and “20” on the other. Edarbi 40 mg tablets: White to nearly white round tablets, 7.6 mm in diameter, debossed “ASL” on one side and “40” on the other. Edarbi 80 mg tablets: White to nearly white round tablets, 9.6 mm in diameter, debossed “ASL” on one side and “80” on the other. |
Edarbi 20 mg tablets: Each tablet contains 20 mg of azilsartan medoxomil (as potassium).
Edarbi 40 mg tablets: Each tablet contains 40 mg of azilsartan medoxomil (as potassium).
Edarbi 80 mg tablets: Each tablet contains 80 mg of azilsartan medoxomil (as potassium).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Azilsartan medoxomil |
Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. |
| List of Excipients |
|---|
|
Mannitol (E421) |
Aluminum blisters
Pack sizes: 14, 28, 56 or 98 tablets; or
Aluminum blisters integrated with desiccant.
Pack sizes: 14, 28, 30, 56, 90 or 98 tablets.
Not all pack sizes may be marketed.
Takeda Pharma A/S, Delta Park 45, 2665 Vallensbaek Strand, Denmark
EU/1/11/734/001 14 tablets
EU/1/11/734/002 28 tablets
EU/1/11/734/012 30 tablets
EU/1/11/734/003 56 tablets
EU/1/11/734/013 90 tablets
EU/1/11/734/004 98 tablets
EU/1/11/734/005 14 tablets
EU/1/11/734/006 28 tablets
EU/1/11/734/014 30 tablets
EU/1/11/734/007 56 tablets
EU/1/11/734/015 90 tablets
EU/1/11/734/008 98 tablets
EU/1/11/734/016 14 tablets
EU/1/11/734/009 28 tablets
EU/1/11/734/017 30 tablets
EU/1/11/734/010 56 tablets
EU/1/11/734/018 90 tablets
EU/1/11/734/011 98 tablets
EU/1/11/734/019 14 tablets
EU/1/11/734/020 28 tablets
EU/1/11/734/021 56 tablets
EU/1/11/734/022 98 tablets
EU/1/11/734/023 14 tablets
EU/1/11/734/024 28 tablets
EU/1/11/734/025 56 tablets
EU/1/11/734/026 98 tablets
EU/1/11/734/027 14 tablets
EU/1/11/734/028 28 tablets
EU/1/11/734/029 56 tablets
EU/1/11/734/030 98 tablets
Date of first authorisation: 7 December 2011
Date of latest renewal:14 November 2016
| Drug | Countries | |
|---|---|---|
| EDARBI | Austria, Brazil, Canada, Germany, Estonia, Hong Kong, Croatia, Ireland, Lithuania, Poland, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
